Can a sick-day protocol improve outcomes in Chronic Kidney Disease?
病假方案可以改善慢性肾脏病的治疗结果吗?
基本信息
- 批准号:9183807
- 负责人:
- 金额:$ 28.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Renal Failure with Renal Papillary NecrosisAdherenceAmbulatory Care FacilitiesBiological PreservationBlood Chemical AnalysisCaringChronic Kidney FailureClinicalCodeCommunitiesComputerized Medical RecordConsensusConsentCreatinineDetectionDialysis procedureDiureticsEffectivenessElectrolytesElectronic Health RecordEmergency department visitEnrollmentEvaluationEventFrequenciesGuidelinesHealthcare SystemsHospitalizationHospitalsHypotensionIllness DaysIncidenceInstructionInternational Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)InterventionKidneyKidney DiseasesLeadLinear ModelsMarylandMeasurementMeasuresMethodsModificationMonitorNational Health ServicesOutcomeParticipantPatient MonitoringPatientsPharmaceutical PreparationsPopulationPreventionProtocols documentationProviderRandomizedRenal functionRenin-Angiotensin SystemResearch DesignResolutionRiskRuralSafetySelf ManagementSerumSiteStagingSurveysSystemTelephoneTestingThinkingTimeTranslational ResearchUrban HospitalsVisitVoicearmbaseblood pressure regulationdesignexperiencehazardhealth service usehigh riskimproved outcomenovelpragmatic trialpreventprogramsrandomized trialresponseservice utilizationstudy populationtreatment as usualtrial comparingvirtual laboratory
项目摘要
The benefits to CKD patients of renin angiotensin system (RAS) blockers and diuretics are well-established;
however, these agents may become hazardous on “sick-days” that lead to volume depletion and increase the
risk of renal function loss and acute kidney injury (AKI). It is not known how frequent significant sick-days
occur in CKD patients, or whether a self-managed sick-day protocol (SDP) that temporarily holds RAS
blocker and diuretics is safe or effective in preserving renal function, or preventing AKI. Hypothesis: a self-
managed SDP in CKD patients will safely reduce renal function loss, AKI episodes and preventable service
utilization. Study Design: 6-month pragmatic randomized trial. Study population: Stage III-V, pre-dialysis
CKD patients, deemed high-risk based on treatment with a RAS blocker and loop diuretic. Study site: VA
Maryland Health Care System (VAMHCS) including a network of two hospitals, and urban and rural outpatient
clinics. Intervention: Intervention participants will be provided with instructions for an SDP with monthly
monitoring via an interactive voice-survey dial-response system (IVSDRS) to track frequency of sick-days and
self-management responses to these incidents. Usual care participants will be educated on the significance of
sick-days and encouraged to call providers for guidance on therapy when sick-days occur. All participants
will be asked to obtain measures of renal function when sick. Specific aims: 1) Compare the safety and
effectiveness of the SDP intervention versus usual care. 2) Determine the incidence of sick-days in the
intervention arm using remote IVSDRS monitoring and by end-of-study survey of all participants. 3) Evaluate
intervention arm participants' usage of, and adherence to, the SDP with remote IVSDRS monitoring. Study
measurements: Baseline and 6-month measures of renal function, incidental measurement of renal function
and blood chemistries proximate to significant sick-days, electronic health record (EHR) review for
hospitalizations and episodes of AKI (ICD-10 code-defined), IVSRDS monitoring for significant sick-days and
adherence to the SDP. Outcomes: 6-month change in renal function, incidence of ICD-10 defined-AKI,
frequency of serum creatinine-defined AKI in the ambulatory setting, IVSDRS detection of sick-day incidents,
and intervention arm participants' cessation and timely resumption of RAS blocker and/or diuretics,
Analytical plans: Comparison between intervention and usual care participants of renal function change,
and frequency of AKI and hospitalization using generalized linear models and Poisson regression methods,
respectively. Similar regression methods will be used to determine the adjusted frequency rate of sick-day
incidents and participant response to sick-days. Expected findings: Use of a self-managed SDP in high-risk
CKD patients is feasible to safely administer with preliminary evidence for preservation of renal function, and
prevention of AKI.
肾素血管紧张素系统(RAS)阻滞剂和利尿剂对CKD患者的益处是确凿的;
然而,这些药剂可能在“病假”时变得危险,从而导致容量消耗和增加
肾功能丧失和急性肾损伤(AKI)的风险。目前尚不清楚重大病假的频率有多高
发生在CKD患者中,或者是临时控制RAS的自我管理病假方案(SDP)
阻滞剂和利尿剂在保护肾功能或预防AKI方面是安全或有效的。假设:一种自我
CKD患者经管理的SDP将安全地减少肾功能损失、AKI事件和可预防的服务
利用率。研究设计:为期6个月的实用型随机试验。研究人群:III-V期,透析前
CKD患者,根据RAS阻滞剂和环状利尿剂的治疗被认为是高危患者。研究地点:弗吉尼亚州
马里兰州医疗保健系统(VAMHCS),包括两家医院和城乡门诊网络
诊所。干预:干预参与者将获得每月一次的SDP说明
通过交互式语音调查拨号响应系统(IVSDRS)进行监测,以跟踪病假频率和
对这些事件的自我管理反应。将对日常护理参与者进行教育,使其了解
请病假,并鼓励在病假发生时致电医疗服务提供者寻求治疗指导。所有参与者
会被要求在生病时获得肾功能的测量结果。具体目标:1)比较安全和
SDP干预与常规护理的有效性。2)确定年内病假发生率
使用远程IVSDRS监测的干预组,并通过对所有参与者的研究结束调查。3)评估
干预ARM参与者使用并遵守远程IVSDRS监控的SDP。学习
测量:基线和6个月肾功能测量,附带肾功能测量
和接近大病假的血液化学,电子健康记录(EHR)审查
AKI(ICD-10代码定义)的住院和发作,大病假和IVSRDS监测
遵守SDP。结果:6个月内肾功能的变化,ICD-10定义的AKI的发生率,
门诊环境中血肌酐定义的AKI的频率,病假事件的IVSDRS检测,
和干预ARM参与者停止和及时恢复RAS阻滞剂和/或利尿剂,
分析方案:肾功能改变干预与常规护理参与者的比较
使用广义线性模型和泊松回归方法计算急性心肌梗死和住院的频率,
分别进行了分析。将使用类似的回归方法来确定调整后的病假频率比率
事件和参与者对病假的反应。预期结果:在高风险人群中使用自我管理的SDP
CKD患者在有初步证据保护肾功能的情况下可以安全地给予治疗,并且
预防AKI。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY C FINK其他文献
JEFFREY C FINK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY C FINK', 18)}}的其他基金
Can a sick-day protocol improve outcomes in Chronic Kidney Disease?
病假方案可以改善慢性肾脏病的治疗结果吗?
- 批准号:
9339683 - 财政年份:2016
- 资助金额:
$ 28.35万 - 项目类别:
Care Coordination/Telehealth to address patient safety and poor outcomes in CKD
护理协调/远程医疗可解决 CKD 患者的安全和不良预后问题
- 批准号:
8856231 - 财政年份:2014
- 资助金额:
$ 28.35万 - 项目类别:
Care Coordination/Telehealth to address patient safety and poor outcomes in CKD
护理协调/远程医疗可解决 CKD 患者的安全和不良预后问题
- 批准号:
8709709 - 财政年份:2014
- 资助金额:
$ 28.35万 - 项目类别:
Patient safety monitoring in kidney disease with an eDiary.
使用电子日记监测肾脏疾病的患者安全。
- 批准号:
8732628 - 财政年份:2013
- 资助金额:
$ 28.35万 - 项目类别:
Patient safety monitoring in kidney disease with an eDiary.
使用电子日记监测肾脏疾病的患者安全。
- 批准号:
8636253 - 财政年份:2013
- 资助金额:
$ 28.35万 - 项目类别:
Do Patient Safety Events Account for Adverse Outcomes in CKD?
患者安全事件会导致 CKD 的不良后果吗?
- 批准号:
8332112 - 财政年份:2011
- 资助金额:
$ 28.35万 - 项目类别:
Do Patient Safety Events Account for Adverse Outcomes in CKD?
患者安全事件会导致 CKD 的不良后果吗?
- 批准号:
8726971 - 财政年份:2011
- 资助金额:
$ 28.35万 - 项目类别:
Do Patient Safety Events Account for Adverse Outcomes in CKD?
患者安全事件会导致 CKD 的不良后果吗?
- 批准号:
8184497 - 财政年份:2011
- 资助金额:
$ 28.35万 - 项目类别:
Do Patient Safety Events Account for Adverse Outcomes in CKD?
患者安全事件会导致 CKD 的不良后果吗?
- 批准号:
8540414 - 财政年份:2011
- 资助金额:
$ 28.35万 - 项目类别:
Does underrecognition of kidney disease affect patient safety?
对肾脏疾病认识不足是否会影响患者安全?
- 批准号:
8704924 - 财政年份:2010
- 资助金额:
$ 28.35万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 28.35万 - 项目类别:
Fellowship Programs














{{item.name}}会员




